Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD59 Chimeric Recombinant Rabbit Monoclonal Antibody (193-27)
CD59 Chimeric Recombinant Rabbit Monoclonal Antibody (193-27)
Supplier: Thermo Scientific MA548273
Description
CD59 Chimeric Recombinant Monoclonal Antibody for ICC/IF, IHC, Flow

Specifications
CD59 Chimeric | |
Recombinant Monoclonal | |
1 mg/mL | |
PBS with 0.02% ProClin 300 | |
P13987 | |
CD59 | |
This antibody was raised by immunizng mice with stimulated human leukocytes. | |
200 μg | |
Primary | |
Human | |
Antibody | |
IgG κ |
Flow Cytometry, Immunohistochemistry, Immunocytochemistry | |
193-27 | |
Unconjugated | |
CD59 | |
16.3A5; 1F5; 1F5 antigen; 20 kDa homologous restriction factor; AA987121; Cb59b molecule; CD59; CD59 antigen; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 glycoprotein; CD59 molecule; CD59 molecule (CD59 blood group); CD59 molecule, complement regulatory protein; Cd59a; CD59a antigen; CD59A glycoprotein; Cd59b; CD59b antigen; CD59B glycoprotein; CD59b moleucle, complement regulatory protein; complement inhibitor CD59; complement regulatory protein; EJ16; EJ30; EL32; G344; HRF20; HRF-20; human leukocyte antigen MIC11; Ly-6-like protein; lymphocytic antigen CD59/MEM43; MACIF; MAC-inhibitory protein; MACIP; MAC-IP; MEM43; MEM43 antigen; membrane attack complex (MAC) inhibition factor; membrane attack complex inhibition factor; Membrane inhibitor of reactive lysis; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20; protectin; surface anitgen recognized by monoclonal antibody 16.3A5; T cell-activating protein | |
Rabbit | |
Protein A | |
RUO | |
966 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction